PDCD1 and melanoma: Recently, the approval of relatlimab (an ICI targeting LAG-3) based on a study showing that combined relatlimab with anti-PD-1 doubled the progression free survival of advanced melanoma patients compared to patients receiving PD-1 monotherapy highlights the growing therapeutic potential of ICIs [169].